These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 28455891)

  • 1. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.
    Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J
    Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paliperidone palmitate in short- and long-term treatment of schizophrenia.
    Valsecchi P; Barlati S; Garozzo A; Deste G; Nibbio G; Turrina C; Sacchetti E; Vita A
    Riv Psichiatr; 2019; 54(6):235-248. PubMed ID: 31909750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.
    Jones MP; Nicholl D; Trakas K
    Int J Clin Pharmacol Ther; 2010 Jun; 48(6):383-99. PubMed ID: 20497747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
    Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
    BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
    Decuypere F; Sermon J; Geerts P; Denee TR; De Vos C; Malfait B; Lamotte M; Mulder CL
    PLoS One; 2017; 12(6):e0179049. PubMed ID: 28614404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone extended-release in the short- and long-term treatment of schizophrenia.
    Valsecchi P; Garozzo A; Nibbio G; Barlati S; Deste G; Turrina C; Sacchetti E; Vita A
    Riv Psichiatr; 2019; 54(2):43-58. PubMed ID: 30985829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.
    Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I
    J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816
    [No Abstract]   [Full Text] [Related]  

  • 16. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Owen RT
    Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
    Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
    Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
    Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
    J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
    J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.